Eagle Pharmaceuticals Inc (EGRX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2016||Independent Chairman of the Board|
|57||2017||Chief Executive Officer, Independent Director|
|47||2017||Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer|
|65||2013||Chief Financial Officer|
|56||2016||Executive Vice President, Chief Medical Officer|
- BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58
- BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing
- BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals
- BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
- BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98